TR-57 (Madera Therapeutics)

N/A

Report date: 2024/02/06 13:05:25
NME

Base Information

Drug NameTR-57 (Madera Therapeutics)
Drug Alias NameTR-57 (Madera Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCaseinolytic protease P activators
TargetsCaseinolytic protease P
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMadera Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesMadera Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A